Literature DB >> 35300463

Checking the chart in severe gastritis: a case in point.

Sundeep Ghuman1, Raphael Luber1, Ula Mahadeva2,3, Debra H Josephs4, Mark A Samaan1.   

Abstract

Entities:  

Keywords:  cancer; dyspepsia; immune response; infliximab

Year:  2021        PMID： 35300463      PMCID： PMC8862444          DOI： 10.1136/flgastro-2021-101846

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  5 in total

1.  Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.

Authors:  Bhavana Bhagya Rao; Scott Robertson; Jessica Philpott
Journal:  Am J Gastroenterol       Date:  2019-02       Impact factor: 10.864

2.  Morphological spectrum of immune check-point inhibitor therapy-associated gastritis.

Authors:  Melanie Johncilla; Shilpa Grover; Xuchen Zhang; Dhanpat Jain; Amitabh Srivastava
Journal:  Histopathology       Date:  2020-02-18       Impact factor: 5.087

Review 3.  British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.

Authors:  Nick Powell; Hajir Ibraheim; Tim Raine; Richard A Speight; Sophie Papa; Oliver Brain; Michael Green; Mark A Samaan; Lavinia Spain; Nadia Yousaf; Nikki Hunter; Lucy Eldridge; Polychronis Pavlidis; Peter Irving; Bu'Hussain Hayee; Samra Turajlic; James Larkin; James O Lindsay; Martin Gore
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-07

Review 4.  Cancer immunotherapies targeting the PD-1 signaling pathway.

Authors:  Yoshiko Iwai; Junzo Hamanishi; Kenji Chamoto; Tasuku Honjo
Journal:  J Biomed Sci       Date:  2017-04-04       Impact factor: 8.410

5.  Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis.

Authors:  Hajir Ibraheim; Samantha Baillie; Mark A Samaan; Hamzah Abu-Sbeih; Yinghong Wang; Nicholas J Talley; Michael P Jones; Nick Powell
Journal:  Aliment Pharmacol Ther       Date:  2020-09-13       Impact factor: 8.171
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.